Duloxetine in the treatment of irritable bowel syndrome: An open-label pilot study

Human Psychopharmacology

Volumn 24, Issue 5, 2009, Pages 423-428

  Brennan, Brian P ^a,b   Fogarty, Kate V ^a   Roberts, Jacqueline L ^a   Reynolds, Karina A ^a   Pope Jr , Harrison G ^a,b   Hudson, James I ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Duloxetine; IBS; Irritable bowel syndrome; Pain

Indexed keywords

DULOXETINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; THIOPHENE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANORGASMIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FAMILY STRESS; FEMALE; HARD FECES; HUMAN; INSOMNIA; IRRITABLE COLON; LOOSE FECES; MAJOR DEPRESSION; MALE; NAUSEA; NIGHT SWEAT; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; WORK DISABILITY; XEROSTOMIA; DISABILITY; HOSPITALIZATION; MIDDLE AGED; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ADULT; ANALGESICS; ANTIDEPRESSIVE AGENTS; DISABILITY EVALUATION; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70149108550     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1038     Document Type: Article

References (37)

1. Arnold LM, Rosen A, Pritchett YL, et al. 2005. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119: 5-15.
2. Brennan BP, Roberts JL, Fogarty KV, Reynolds KA, Jonas JM, Hudson JI. 2008. Memantine in the treatment of binge eating disorder: an open-label, prospective trial. Int J Eat Disord.
3. Charmandari E, Tsigos C, Chrousos G. 2005. Endocrinology of the stress response. Annu Rev Physiol 67: 259-284.
4. Cleeland CS, Ryan KM. 1994. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129-138.
5. Creed F, Ratcliffe J, Fernandes L, et al. 2005. Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders. Br J Psychiatry 186: 507-515.
6. Delvaux M. 2002. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut V 51 (Suppl 1): i67-71.
7. Drossman DA. 2006. Rome III:the functional gastrointestinal disorders. Degnon Associates. McLean, VA.
8. Drossman DA, Toner BB, Whitehead WE, et al. 2003. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125: 19-31.
9. Everhart JE, Renault PF. 1991. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 100: 998-1005.
10. Greenbaum DS, Mayle JE, Vanegeren LE, et al. 1987. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 32: 257-266.
11. Greenwood-Van Meerveld B, Johnson AC, Cochrane S, Schulkin J, Myers DA. 2005. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. Neurogastroenterol Motil 17: 415-422.
12. Hartford J, Kornstein S, Liebowitz M, et al. 2007. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22: 167-174.
13. Heaton KW, O'Donnell LJ. 1994. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol 19: 28-30.
14. Hudson JI, Mangweth B, Pope HG Jr, et al. 2003. Family study of affective spectrum disorder. Arch Gen Psychiatry 60: 170-177.
15. Hudson JI, Pope HG. 1994. The concept of affective spectrum disorder: relationship to fibromyalgia and other syndromes of chronic fatigue and chronic muscle pain. Baillieres Clin Rheumatol 8: 839-856.
16. Hudson JI, Pope HG Jr. 1990. Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? Am J Psychiatry 147: 552-564.
17. Inadomi JM, Fennerty MB, Bjorkman D. 2003. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 18: 671-682.
18. Jones MP, Dilley JB, Drossman D, Crowell MD. 2006. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 18: 91-103.
19. Larauche M, Bradesi S, Million M, et al. 2008. Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. Am J Physiol Gastrointest Liver Physiol 294: G1033-G1040.
20. Lydiard RB. 2001. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 8(Suppl 62): 38-45 discussion 46-7.
21. Lydiard RB. 2007. Psychopharmacology in the treatment of irritable bowel syndrome. Primary Psychiatry 14: 41-42 45-50.
22. Masand PS, Gupta S, Schwartz TL, Virk S, Hameed A, Kaplan DS. 2005. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry 7: 162-166.
23. Masand PS, Gupta S, Schwartz TL, et al. 2002. Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. Prim Care Companion J Clin Psychiatry 4: 12-16.
24. Mayer EA, Naliboff BD, Chang L, Coutinho SV. 2001. V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 280: G519-524.
25. Mertz HR. 2003. Irritable bowel syndrome. N Engl J Med 349: 2136-2146.
26. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. 2005. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 54: 601-607.
27. Patel SM, Stason WB, Legedza A, et al. 2005. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 17: 332-340.
28. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. 1998. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 43: 400-411.
29. Posserud I, Agerforz P, Ekman R, Bjornsson ES, Abrahamsson H, Simren M. 2004. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 53: 1102-1108.
30. Raskin J, Pritchett YL, Wang F, et al. 2005. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6: 346-356.
31. Rynn M, Russell J, Erickson J, et al. 2008. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25: 182-189.
32. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 20(Suppl 59): 22-33. quiz 34-57.
33. Stout SC, Owens MJ, Nemeroff CB. 2002. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 300: 1085-1092.
34. Svensson TH, Usdin T. 1978. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: alpha-receptor mediation. Science 202: 1089-1091.
35. Tache Y, Million M, Nelson AG, Lamy C, Wang L. 2005. Role of corticotropin-releasing factor pathways in stress-related alterations of colonic motor function and viscerosensibility in female rodents. Gend Med 2: 146-154.
36. Tache Y, Monnikes H, Bonaz B, Rivier J. 1993. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann NY Acad Sci 697: 233-243.
37. Videlock EJ, Chang L. 2007. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am 36: 665-685.